In summary, our work provides a novel framework for exploring targeted anti-tumor therapies, leveraging the bi-functional anti-tumour advantage of ZHPV16E7-GrB, with one function mediated by ZHPV16E7, inhibiting the migration of HPV16+ cervical cancer cells by suppressing EMT, and the other function mediated by GrB, inducing the joint cell death including apoptosis and pyroptosis to enhance anti-tumor immunity and efficacy. The gene discussed is GZMB; the disease is neoplasm.